scholarly journals 195 Intravenous antibiotics effects on spirometrics parameters of Cystic Fibrosis (CF) patients with acute pulmonary exacerbation infected with Pseudomonas aeruginosa

2006 ◽  
Vol 5 ◽  
pp. S45
Author(s):  
C.I.S. Santos ◽  
M.A.G.O. Ribeiro ◽  
S.R.M. Paula ◽  
R.T. Mendes ◽  
A.E Ribeiro ◽  
...  
2011 ◽  
Vol 60 (2) ◽  
pp. 157-161 ◽  
Author(s):  
Typhaine Billard-Pomares ◽  
Stéphanie Herwegh ◽  
Nathalie Wizla-Derambure ◽  
Dominique Turck ◽  
René Courcol ◽  
...  

Early detection of Pseudomonas aeruginosa and early aggressive treatment are recommended to delay chronic infection in cystic fibrosis (CF) patients. The aim of this study was to assess a quantitative PCR (q-PCR) assay for the diagnosis of early P. aeruginosa colonization in 23 young CF patients (group A, age range 7–18 years) and to survey the eradication of P. aeruginosa in 10 young CF patients (group B, age range 5–18 years) after an initial antibiotic treatment. q-PCR results for consecutive sputum samples from each patient during a period of 18 months were compared with bacterial cultures during the same period plus an additional period of 12 months, and with concomitant clinical signs of pulmonary exacerbation. The q-PCR and bacterial cultures were negative for 17 of the 23 patients in group A and six of the 10 patients in group B during the study period. However, consecutive positive q-PCR results were observed for one patient in group A and three patients in group B, while the bacterial cultures for the same sputum sample remained negative. They preceded positive P. aeruginosa bacterial cultures at 7 and 8 months for two patients in group B. These positive results were associated with a worsening of the clinical status of patients, but pulmonary exacerbation appeared non-specific for the diagnosis of early P. aeruginosa colonization since pulmonary exacerbations were observed in patients in whom q-PCR or bacterial culture remained negative. In conclusion, q-PCR may be a useful additional tool to provide information on the P. aeruginosa status of CF patients.


2021 ◽  
pp. 106687
Author(s):  
Frederick W. Woodley ◽  
Emrah Gecili ◽  
Rhonda D. Szczesniak ◽  
Chandra L. Shrestha ◽  
Christopher J. Nemastil ◽  
...  

2005 ◽  
Vol 24 (1) ◽  
pp. 88-96 ◽  
Author(s):  
L. Béghin ◽  
F. Gottrand ◽  
L. Michaud ◽  
H. Vodougnon ◽  
N. Wizla-Derambure ◽  
...  

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 575 ◽  
Author(s):  
Kate Skolnik ◽  
Bradley S. Quon

Pulmonary exacerbations are common events in cystic fibrosis and have a profound impact on quality of life, morbidity, and mortality. Pulmonary exacerbation outcomes remain poor and a significant proportion of patients fail to recover their baseline lung function despite receiving aggressive treatment with intravenous antibiotics. This focused review provides an update on some of the recent advances that have taken place in our understanding of the epidemiology, pathophysiology, diagnosis, and management of pulmonary exacerbations in cystic fibrosis as well as direction for future study.


Sign in / Sign up

Export Citation Format

Share Document